Ilsung Is (003120) Fundamentals 2026 — Revenue Analysis | SniperIQ
Ilsung Is (003120) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩145.0B, trading at ₩20250.00 on the KSC. This SniperIQ fundamentals page covers Ilsung Is's valuation, profitability (net margin 1.9%), revenue (₩64.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ilsung Is's market cap?
Ilsung Is (003120) has a market capitalization of approximately ₩145.0B, trading at ₩20250.00 on the KSC. Market cap moves with the live share price.
What is Ilsung Is's P/E ratio?
Ilsung Is's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ilsung Is?
Ilsung Is runs a net profit margin of 1.9%, a gross margin of 42.1%, and an operating margin of -8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ilsung Is generate?
Ilsung Is reported revenue of ₩64.3B for fiscal year 2025, with net income of ₩1.2B and earnings per share (EPS) of 170. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ilsung Is pay a dividend?
Ilsung Is offers a trailing dividend yield of about 5.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Ilsung Is financially healthy?
Ilsung Is carries a debt-to-equity ratio of 0.00x and a current ratio of 12.24x, with a market beta of -0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ilsung Is a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ilsung Is (003120) the key facts are: market cap ₩145.0B, revenue ₩64.3B, 52-week range 18100-29300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ilsung Is's full fundamentals live
Get Ilsung Is's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.